A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention

Trial Profile

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Erenumab (Primary)
  • Indications Migraine with aura; Migraine without aura
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 23 Aug 2017 Results assessing efficacy and safety of Erenumab in an interim analysis conducted in patients with episodic migraine who completed 1-year open-label follow-up of the study, published in the Neurology.
    • 21 Apr 2016 Planned End Date changed from 1 Mar 2020 to 1 Nov 2019.
    • 21 Apr 2016 Interim results of the ongoing OLE study presented at the 68th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top